Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Clinical trial NCT02825836 · UNKNOWN

Trial details

NCT number: NCT02825836
Sponsor: Telios Pharma, Inc.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory B Cell Malignancies Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Treatment-Naive B Cell Malignancies

Start date: 2016-08-26
Primary completion: 2024-12-01
Enrollment: 130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.